| Species |
Human |
| Protein Construction |
LAIR2/CD306 (Gln22-Pro152)
Accession # Q6ISS4-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
LAIR2/CD306, His & Avi, Human captured on CM5 Chip via AntiHis Antibody can bind Native Human Collagen I protein in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
17 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 20-25 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The leukocyte-associated immunoglobulin-like receptor 2 (LAIR2) shows increased expression during pregnancy and its reduced expression is associated with pregnancy complications. Although LAIR2 was expressed in the human placenta villus and decidua in the first trimester of pregnancy, it was not expressed in mouse tissues. Knockdown of LAIR2 markedly improved cell viability and inhibited the invasive ability of HTR8/SVneo cells. |
| Synonyms |
LAIR-2; CD306; LAIR2; MGC71634; XXbac-BCX535A19.6 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
